Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway that is in Phase II clinical trials to treat glioblastoma multiforme. The company is also developing TRX-E-002-1 (Cantrixil), a third-generation benzopyran molecule, which is in Phase I clinical trials to treat ovarian cancer. It has collaboration agreements with The University of York, The Children's Cancer Institute Australia, The Mater Institute in Queensland, the University of Boston, and St Jude Children's Research Hospital, as well as Dana-Farber Cancer Institute. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61-2-9472-4101
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$90,000.00
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Kazia Therapeutics (NASDAQ:KZIA) Frequently Asked Questions
What is Kazia Therapeutics' stock symbol?
Kazia Therapeutics trades on the NASDAQ under the ticker symbol "KZIA."
Has Kazia Therapeutics been receiving favorable news coverage?
Media coverage about KZIA stock has been trending somewhat positive on Friday, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kazia Therapeutics earned a coverage optimism score of 2.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the stock's share price in the immediate future.
Who are some of Kazia Therapeutics' key competitors?
Some companies that are related to Kazia Therapeutics include Scpharmaceuticals (SCPH), Pharmaxis (PXSLY), Oramed Pharmaceuticals (ORMP), Zosano Pharma (ZSAN), Medicure (MCUJF), AEterna Zentaris (AEZS), Aquinox Pharmaceuticals (AQXP), Aravive (ARAV), Agile Therapeutics (AGRX), Alimera Sciences (ALIM), NewLink Genetics (NLNK), vTv Therapeutics (VTVT), Seelos Therapeutics (SEEL), Moleculin Biotech (MBRX) and Akari Therapeutics (AKTX).
Who are Kazia Therapeutics' key executives?
Kazia Therapeutics' management team includes the folowing people:
- Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (, CEO, MD & Exec. Director (Age 46)
- Ms. Gabrielle Heaton, Director of Fin. & Admin.
- Ms. Catherine Jane Hill, Company Sec. (Age 60)
- Kym Robins, Director of Marketing & Communications
- Dr. Justine R. Stehn B.Sc (Hons), Ph.D., Director of ATM Program
How do I buy shares of Kazia Therapeutics?
Shares of KZIA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kazia Therapeutics' stock price today?
One share of KZIA stock can currently be purchased for approximately $3.50.
How big of a company is Kazia Therapeutics?
Kazia Therapeutics has a market capitalization of $16.91 million and generates $90,000.00 in revenue each year. The company earns $-4,680,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis.
What is Kazia Therapeutics' official website?
How can I contact Kazia Therapeutics?
Kazia Therapeutics' mailing address is Three International Towers Level 24 300 Barangaroo Avenue, Sydney C3, 2000. The company can be reached via phone at 61-2-9472-4101 or via email at [email protected]
MarketBeat Community Rating for Kazia Therapeutics (NASDAQ KZIA)
MarketBeat's community ratings are surveys of what our community members think about Kazia Therapeutics and other stocks. Vote "Outperform" if you believe KZIA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KZIA will underperform the S&P 500 over the long term. You may vote once every thirty days.
